Geldanamycin

WikiDoc Resources for Geldanamycin
Articles
Most recent articles on Geldanamycin Most cited articles on Geldanamycin Review articles on Geldanamycin Articles on Geldanamycin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Geldanamycin Images of Geldanamycin Photos of Geldanamycin Podcasts & MP3s on Geldanamycin Videos on Geldanamycin
Evidence Based Medicine
Cochrane Collaboration on Geldanamycin Bandolier on Geldanamycin TRIP on Geldanamycin
Clinical Trials
Ongoing Trials on Geldanamycin at Clinical Trials.gov Trial results on Geldanamycin Clinical Trials on Geldanamycin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Geldanamycin NICE Guidance on Geldanamycin NHS PRODIGY Guidance FDA on Geldanamycin CDC on Geldanamycin
Books
Books on Geldanamycin
News
Geldanamycin in the news Be alerted to news on Geldanamycin News trends on Geldanamycin
Commentary
Blogs on Geldanamycin
Definitions
Definitions of Geldanamycin
Patient Resources / Community
Patient resources on Geldanamycin Discussion groups on Geldanamycin Patient Handouts on Geldanamycin Directions to Hospitals Treating Geldanamycin Risk calculators and risk factors for Geldanamycin
Healthcare Provider Resources
Symptoms of Geldanamycin Causes & Risk Factors for Geldanamycin Diagnostic studies for Geldanamycin Treatment of Geldanamycin
Continuing Medical Education (CME)
CME Programs on Geldanamycin
International
Geldanamycin en Espanol Geldanamycin en Francais
Business
Geldanamycin in the Marketplace Patents on Geldanamycin
Experimental / Informatics
List of terms related to Geldanamycin

Geldanamycin is a benzoquinone ansamycin antibiotic that binds to Hsp90 (Heat Shock Protein 90) and alters its function. HSP90 client proteins play important roles in the regulation of the cell cycle, cell growth, cell survival, apoptosis, angiogenesis and oncogenesis.

Geldanamycin induces the degradation of proteins that are mutated in tumor cells such as v-Src, Bcr-Abl and p53 preferentially over their normal cellular counterparts. This effect is mediated via HSP90. Despite its potent antitumor potential, geldanamycin presents several major drawbacks as a drug candidate (namely, hepatotoxicity) that have led to the development of geldanamycin analogues, in particular analogues containing a derivatisation at the 17 position:

• 17-AAG

• 17-DMAG

References

• Bedin M, Gaben AM, Saucier C, Mester J. Int J Cancer. 2004 May 1;109(5):643-52. Geldanamycin, an inhibitor of the chaperone activity of HSP90, induces MAPK-independent cell cycle arrest.

External links

• A comprehensive review about Geldanamycin, 17AAG and 17DMAG